Mallinckrodt Plc, a pharmaceutical company based in Ireland, specializes in developing, manufacturing, and distributing specialty pharmaceutical products for autoimmune and rare diseases. With a risk rating score of 40.4, Mallinckrodt PLC is considered to pose severe risk. The company's focus areas include neurology, rheumatology, nephrology, pulmonology, and ophthalmology, as well as immunotherapy and neonatal respiratory critical care therapies. Mallinckrodt operates in two segments - Specialty Brands and Specialty Generics, with the former generating the majority of its revenue. Sees significant revenue from the United States.